BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33624534)

  • 21. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning.
    Roland CL; Ye X; Stevens V; Oderda GM
    J Manag Care Spec Pharm; 2019 Jan; 25(1):18-27. PubMed ID: 30589633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
    Klimchak AC; Szabo SM; Qian C; Popoff E; Iannaccone S; Gooch KL
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1426-1437. PubMed ID: 34595954
    [No Abstract]   [Full Text] [Related]  

  • 24. Place of care and costs associated with acute episodes and remission in schizophrenia.
    McIntyre RS; Higa S; Doan QV; Amari DT; Mercer D; Gillard P; Harrington A
    J Manag Care Spec Pharm; 2023 May; 29(5):499-508. PubMed ID: 37121252
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 27. Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
    Shei A; Rice JB; Kirson NY; Bodnar K; Enloe CJ; Birnbaum HG; Holly P; Ben-Joseph R
    J Manag Care Spec Pharm; 2015 Oct; 21(10):902-12. PubMed ID: 26402390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 29. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
    Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
    Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
    Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
    J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct health care costs associated with COVID-19 in the United States.
    DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
    J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
    Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
    J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [No Abstract]   [Full Text] [Related]  

  • 34. Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone.
    Ben-Joseph R; Bell JA; Brixner D; Kansal A; Paramore C; Chitnis A; Holly P; S Burgoyne D
    J Manag Care Spec Pharm; 2016 Apr; 22(4):358-66. PubMed ID: 27023689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
    Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
    Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [No Abstract]   [Full Text] [Related]  

  • 37. Differences in healthcare utilization and associated costs between patients prescribed vs. nonprescribed opioids during an inpatient or emergency department visit.
    Xie L; Joshi AV; Schaaf D; Mardekian J; Harnett J; Shah ND; Baser O
    Pain Pract; 2014 Jun; 14(5):446-56. PubMed ID: 23809064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Pain Severity and Opioid Use on Health Care Resource Utilization and Costs Among Patients with Knee and Hip Osteoarthritis.
    Wei W; Gandhi K; Blauer-Peterson C; Johnson J
    J Manag Care Spec Pharm; 2019 Sep; 25(9):957-965. PubMed ID: 31456495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.
    Pergolizzi JV; Ma L; Foster DR; Overholser BR; Sowinski KM; Taylor R; Summers KH
    J Manag Care Spec Pharm; 2014 May; 20(5):467-76. PubMed ID: 24761818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.